Clinical and Economic Utility of BTK Inhibitors in CLL

home / peer-exchange / clinical-and-economic-utility-of-btk-inhibitors-in-cll

A panel of experts discuss chronic lymphocytic leukemia, focusing on the integration of Bruton tyrosine kinase inhibitors into the treatment landscape, the economic and access considerations of BTK inhibitor therapy, and future directions and ongoing research opportunities in the management of CLL.

Episodes

June 28th 2024EP. 1: Recent Trends and Innovations in the Management of CLL

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.

June 28th 2024EP. 2: CLL Treatment Landscape: Overview of BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions